DBC-1 Polyclonal Antibody

Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed: 18235501, PubMed: 18235502, PubMed: 19131338, PubMed: 19218236, PubMed: 22446626, PubMed: 23352644, PubMed : 23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed: 20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed: 24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed: 21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway  (PubMed: 24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed: 25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed: 25732823). Represses the transcriptional activator activity of BRCA1 (PubMed: 20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed: 25361978).

The DBC-1 Polyclonal Antibody is a highly specific and reliable tool for the detection and analysis of DBC-1 protein expression in various biological samples. This antibody has been meticulously developed and validated to ensure exceptional performance and accuracy in a wide range of applications, including Western blotting, immunohistochemistry, and immunofluorescence.

The DBC-1 Polyclonal Antibody exhibits exceptional sensitivity and specificity, enabling precise and reliable detection of DBC-1 protein in even low abundance samples. Its high affinity for the target protein ensures minimal background noise, resulting in clear and accurate results.

This antibody has been rigorously tested and validated using a variety of experimental techniques and sample types, ensuring its suitability for diverse research needs. Its robust performance and consistent results make it an ideal choice for researchers and scientists working in the fields of cancer biology, cell signaling, and molecular biology.

The DBC-1 Polyclonal Antibody is manufactured using state-of-the-art techniques and quality control measures to ensure batch-to-batch consistency and reliability. It is produced in compliance with strict quality standards, guaranteeing its superior performance and reproducibility.

With its exceptional specificity, sensitivity, and reliability, the DBC-1 Polyclonal Antibody is an indispensable tool for researchers seeking to unravel the intricate mechanisms underlying DBC-1 protein function and its role in various biological processes.